They found that CCL20 secreted by tumor cells strongly influences the frequencies of immune-suppressive regulatory Treg cells and TH17 populations, thereby supporting the fact that inhibition of the CCR6/CCL20 duo presents a novel therapeutic strategy in cancer treatment [17,34,35]. The gene discussed is CCL20; the disease is cancer.